Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Janna Tuck

Allergy & Immunology Santa Fe, NM Medical Doctor

NPI 1346230646 CMS profile 197550

1651 Galisteo St Ste 8, Santa Fe, NM 87505

Open in the dashboard

General payments

$3,609

185 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Janna Tuck of Santa Fe, NM is reported in the CMS Open Payments database as having received $3,609 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $653 37
2021 General $1,279 64
2020 General $481 28
2019 General $1,196 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janna Tuck
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Janna Tuck were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Janna Tuck Allergy & Immunology median Middle half National median
2019 $1,196 $594 $163–$1,512 $163
2020 $481 $426 $106–$1,233 $114
2021 $1,279 $638 $157–$1,708 $132
2022 $653 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $0 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AstraZeneca Pharmaceuticals LP $956 55 payments
  2. GlaxoSmithKline, LLC. $710 49 payments
  3. CSL Behring $424 18 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $303 13 payments
  5. Grifols USA, LLC $146 4 payments
  6. Shire North American Group Inc $141 2 payments
  7. Novartis Pharmaceuticals Corporation $137 8 payments
  8. OptiNose US, Inc. $120 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $112 6 payments
  10. Regeneron Healthcare Solutions, Inc. $93 5 payments
  11. Other $466 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,598 184 payments
  2. Education $11 1 payment
Products named General payments · program years 2019–2022
  1. FASENRA Respiratory $317 12 payments
  2. HYQVIA $289 8 payments
  3. NUCALA Immunology $263 16 payments
  4. SYMBICORT $249 14 payments
  5. TRELEGY ELLIPTA $244 17 payments
  6. Hizentra $234 9 payments
  7. Privigen $217 8 payments
  8. NUCALA Respiratory $203 16 payments
  9. Haegarda $190 9 payments
  10. FASENRA Respiratory $184 13 payments
  11. Other $1,649 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record